[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626316":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":25,"locations":34,"responsibleParty":53,"collaborators":25,"id":55,"slug":25,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Hangzhou Sciwind Biosciences Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"XW003 Injection","EXPERIMENTAL","once weekly",[13],"Drug: XW003 injection",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: placebo with matching volume",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","XW003 injection","subcutaneous injection",[9],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"placebo with matching volume",[15],[30],{"name":31,"affiliation":32,"role":33},"Qingyun Li, Dr","Ruijin Hospital","PRINCIPAL_INVESTIGATOR",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Rui Jin Hospital","RECRUITING","Shanghai","Shanghai Municipality","200025","China",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49],{"name":31,"role":50,"phone":51,"phoneExt":25,"email":52},"CONTACT","(86)021-34186000","liqingyun68@hotmail.com",{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100626316",false,"NCT07434050","A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 28.0 kg\u002Fm2;\n2. The results of PSG meet the diagnosis criteria of OSA and with an AHI≥15 at screening;\n3. Have been on PAP therapy for at least 3 consecutive months prior to screening and plan to continue PAP therapy during the study;\n4. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. History of endocrine disorders which have significant impact on body weight;\n2. Diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state\u002Fcoma;\n3. HbA1c ≥6.5% at screening;\n4. Fasting blood glucose ≥7.0 mmol\u002FL or 2-hour blood glucose ≥11.1 mmol\u002FL after oral glucose tolerance test (OGTT) at screening; participants with FBG ≥6.1 mmol\u002FL but \\\u003C7.0 mmol\u002FL require OGTT;\n5. Have diagnosis of Cheyne Stokes Respiration, or diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas\u002Fhypopneas ≥50%;\n6. Respiratory and neuromuscular diseases that could interfere with the results of the trial;\n7. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia;\n8. Change of body weight \\>5% within 3 months prior to screening (selfreported);\n9. Have a prior or planned surgical treatment for obesity (except liposuction or abdominoplasty if performed more than 1 year prior to screening);\n10. Have received any medication for body weight loss and blood glucose lowering or medication that could lead to significant body weight increase, within 3 months prior to screening.","ALL","18 Years","75 Years",{"count":65,"type":66},140,"ESTIMATED","INTERVENTIONAL",[69],"PHASE3","The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP",[72,73],"OSA - Obstructive Sleep Apnea","Obesity",[75,76,77,73,78],"XW003","Ecnoglutide","OSA","GLP-1","2026-04-09",{"date":81,"type":82},"2026-04-13","ACTUAL",{"date":84,"type":82},"2026-03-02",{"date":86,"type":66},"2028-06-19",{"name":5,"class":6},1]